Entera Bio (Nasdaq: ENTX) is a small Israeli biotech built around N-Tab, an oral peptide delivery platform that uses chemical wrappers and absorption helpers to protect peptide hormones from stomach acid long enough for them to cross the gut wall and reach the bloodstream intact. The thesis is straightforward: if the platform works at scale, peptide drugs that today require daily or weekly injections could become pills.
The lead asset is EB613, an oral form of teriparatide, the synthetic PTH(1-34) fragment marketed by Eli Lilly as Forteo for postmenopausal osteoporosis. At ENDO 2026 on June 14, 2026, Entera presented full single-tablet PK/PD data showing EB613 achieved a comparable pharmacokinetic and pharmacodynamic profile to Forteo and to the multi-tablet EB613 used in the earlier Phase 2 trial. On the patient-preference questionnaire, 14 of 15 participants preferred the single tablet to the multi-tablet, and all 15 preferred daily oral EB613 to the daily injection. A registrational Phase 3 in 750 postmenopausal women starts late 2026, with topline expected H2 2028. The pipeline also includes EB612 (oral PTH(1-34) for chronic hypoparathyroidism, preclinical stage) and EB618 (oral GLP-1/glucagon dual agonist for obesity, preclinical in non-human primates).
Stories here cover Entera trial readouts, the N-Tab platform's potential to convert injection-only peptide drugs to pills, and the broader oral-peptide competitive set. See [[eb613]], [[teriparatide]], and [[oral-peptide]] for adjacent threads.
Entera Bio (Nasdaq: ENTX) presented full single-tablet EB613 results on June 14 at ENDO 2026 in Chicago as a late-breaking oral. The single-tablet EB613 achieved a comparable pharmacokinetic and pharmacodynamic profile to Forteo (injectable teriparatide) and to the multi-tablet EB613 used in Entera's earlier Phase 2 study in postmenopausal women with osteoporosis. On the administration-experience quality-of-life questionnaire, 14 of 15 study participants preferred the single tablet to the multi-tablet format, and all 15 preferred the daily oral EB613 to the daily injection. Entera plans to advance the single-tablet formulation into the Phase 3 trial in 750 postmenopausal women starting late 2026, with topline expected H2 2028.
Entera Bio (Nasdaq: ENTX) confirmed that its first-in-class oral PTH(1-34) tablet EB613 was selected for a late-breaking oral presentation at ENDO 2026 covering single-tablet data ahead of the 750-patient Phase 3 trial set to start late 2026 in postmenopausal osteoporosis. EB613 applies Entera's N-Tab oral-peptide delivery platform to teriparatide (the active ingredient in Forteo). On the obesity side, Entera will present preclinical PK/PD data on EB618, a first-in-class oral dual GLP-1/glucagon receptor agonist, in non-human primates on Saturday June 13 12:15-1:45 PM CT. The ENDO slot extends Entera's spring narrative beyond the Q1 2026 Phase 3 plan first disclosed in May.
Entera Bio reported Q1 2026 May 8 with $20.4M cash and an updated Phase 3 plan for EB613, an oral once-daily PTH(1-34) tablet that would be the first oral osteoanabolic for postmenopausal osteoporosis. The streamlined Phase 3 protocol — submitted to the FDA in March — covers 750 postmenopausal women with primary endpoint of total hip BMD change from baseline at month 12. Trial initiation is targeted for late 2026, with topline H2 2028 — roughly one year earlier than previously guided. The molecule applies Entera's N-Tab oral peptide platform to teriparatide, the active ingredient in Forteo. The Phase 2 dose-ranging study in 161 patients met primary (PD/bone-turnover biomarker) and secondary (BMD) endpoints.